HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Omnipaque vs. Hexabrix in intravenous DSA of the carotid arteries: randomized double-blind crossover study.

Abstract
A randomized double-blind crossover study using Omnipaque 350 mg l/ml (iohexol) and Hexabrix 320 mg l/ml (ioxaglate) in 53 patients undergoing intravenous digital subtraction angiography of the carotid arteries revealed no significant differences in image quality. Some differences were found in subjective side effects that favored Omnipaque. Nausea was reported in four patients after injection of Hexabrix, and a metallic taste was significantly more frequent (p less than 0.01) with this contrast medium. The patients' preference for Omnipaque was also statistically significant (p less than 0.01). It was concluded that both contrast media are suitable for intravenous digital subtraction angiography.
AuthorsP H Nakstad, S J Bakke, O Kjartansson, J von Krogh
JournalAJNR. American journal of neuroradiology (AJNR Am J Neuroradiol) 1986 Mar-Apr Vol. 7 Issue 2 Pg. 303-4 ISSN: 0195-6108 [Print] United States
PMID3082163 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Contrast Media
  • Iodobenzoates
  • Triiodobenzoic Acids
  • Iohexol
  • Ioxaglic Acid
Topics
  • Adult
  • Aged
  • Angiography (methods)
  • Carotid Arteries (diagnostic imaging)
  • Clinical Trials as Topic
  • Contrast Media
  • Double-Blind Method
  • Female
  • Humans
  • Iodobenzoates
  • Iohexol
  • Ioxaglic Acid
  • Male
  • Middle Aged
  • Random Allocation
  • Subtraction Technique
  • Triiodobenzoic Acids (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: